39 / 210
Ponencias
39
Agradecimientos
Este trabajo se ha realizado gracias a financiación de los pro-
yectos PI15/00079 y CB15/00055, del ISCIII & FEDER; 19873/
GERM/15 Fundación Séneca; Sociedad Española de Hemostasia
y Trombosis, y el premio GATRA de Grifols.
Bibliografía
1. Nygaard KK, Brown GE. Essential thrombophilia: Report of five
cases. Archives of Internal Medicine 1937;59:82-106.
2. Jordan FLJ, Nandorff A. The Familial Tendency in Thrombo-embo-
lic Disease. Acta Medica Scandinavica 1956;156:267-75.
3. Egeberg O. Inherited antithrombin deficiency causing thrombophi-
lia. Thromb Diath Haemorrh 1965;13:516-30.
4. Souto JC, Almasy L, Borrell M, et al. Genetic susceptibility to
thrombosis and its relationship to physiological risk factors: the
GAIT study. Genetic Analysis of Idiopathic Thrombophilia. Am J
Hum Genet 2000;67:1452-9.
5. Zöller B, Li X, Sundquist J, et al.Age- and gender-specific familial ris-
ks for venous thromboembolism: a nationwide epidemiological study
based on hospitalizations in Sweden. Circulation 2011;124:1012-20.
6. Mateo J, Oliver A, Borrell M, et al. Laboratory evaluation and cli-
nical characteristics of 2,132 consecutive unselected patients with
venous thromboembolism-results of the Spanish Multicentric Study
on Thrombophilia (EMET-Study). Thromb Haemost 1997;77:444-51.
7. Bertina RM, Koeleman BP, Koster T, et al. Mutation in blood coa-
gulation factor V associated with resistance to activated protein C.
Nature 1994;369:64-7.
8. Poort SR, Rosendaal FR, Reitsma PH, et al. A common genetic
variation in the 3’-untranslated region of the prothrombin gene is
associated with elevated plasma prothrombin levels and an increase
in venous thrombosis. Blood 1996;88:3698-703.
9. Jick H, Slone D, Westerholm B, et al. Venous thromboembolic disea-
se andABO blood type. A cooperative study. Lancet 1969;1:539-42.
10. Germain M, Chasman DI, de Haan H, et al. Meta-analysis of 65,734
individuals identifies TSPAN15 and SLC44A2 as two susceptibility
loci for venous thromboembolism. Am J HumGenet 2015;96:532-42.
11. Hinds DA, Buil A, Ziemek D, et al. Genome-wide association analy-
sis of self-reported events in 6135 individuals and 252 827 con-
trols identifies 8 loci associated with thrombosis. Hum Mol Genet;
2016;9. pii: ddw037. [Epub ahead of print].
12. Baglin T, Gray E, Greaves M, et al. Clinical guidelines for testing for
heritable thrombophilia. Br J Haematol 2010;149:209-20.
13. LijferingWM, Brouwer JL,Veeger NJ, et al. Selective testing for throm-
bophilia in patients with first venous thrombosis: results froma retrospec-
tive family cohort study on absolute thrombotic risk for currently known
thrombophilic defects in 2479 relatives. Blood 2009;113:5314-22.
14. Mahmoodi BK, Brouwer JL, Ten Kate MK, et al. A prospective
cohort study on the absolute risks of venous thromboembolism and
predictive value of screening asymptomatic relatives of patients
with hereditary deficiencies of protein S, protein C or antithrombin.
J Thromb Haemost 2010;8:1193-200.
15. Van Vlijmen EF, Wiewel-Verschueren S, Monster TB, et al. Com-
bined oral contraceptives, thrombophilia and the risk of venous
thromboembolism: a systematic review and meta-analysis. J Thromb
Haemost 2016;28. DOI: 10.1111/jth.13349. [Epub ahead of print].
16. Martínez-Martínez I, Navarro-Fernández J, Østergaard A, et al.
Amelioration of the severity of heparin-binding antithrombin muta-
tions by posttranslational mosaicism. Blood 2012;120:900-4.
17. Martínez-Martínez I, Navarro-Fernández J, Águila S, et al. The
infective polymerization of conformationally unstable antithrom-
bin mutants may play a role in the clinical severity of antithrombin
deficiency. Mol Med 2012;18:762-70.
18. Simioni P, Tormene D, Tognin G, et al. X-linked thrombophilia with a
mutant factor IX (factor IX Padua). N Engl J Med 2009;361:1671-5.
19. Miyawaki Y, Suzuki A, Fujita J, et al. Thrombosis from a prothrom-
bin mutation conveying antithrombin resistance. N Engl J Med
2012;366:2390-6.
20. Lotta LA, Tuana G, Yu J, et al. Next-generation sequencing study
finds an excess of rare, coding single-nucleotide variants of
ADAMTS13 in patients with deep vein thrombosis. J Thromb Hae-
most 2013;11:1228-39.
21. Watson SP, Lowe GC, Lordkipanidzé M, et al. Genotyping and
phenotyping of platelet function disorders. J Thromb Haemost.
2013;Suppl 1:351-63.
22. Luxembourg B, Delev D, Geisen C, et al. Molecular basis of anti-
thrombin deficiency. Thromb Haemost 2011;105:635-46.
23. Toderici M, de la Morena-Barrio ME, Padilla J, et al. Identification
of Regulatory Mutations in SERPINC1AffectingVitamin D Respon-
se Elements Associated with Antithrombin Deficiency. PLoS One
2016;11:e0152159.
24. De la Morena-Barrio ME, Martínez-Martínez I, de Cos C, et al.
Hypoglycosylation is a common finding in antithrombin deficiency
in the absence of a
SERPINC1
gene defect. J Thromb Haemost 2016
[In press].
25. Kottke-Marchant K, Duncan A. Antithrombin deficiency: issues in
laboratory diagnosis. Arch Pathol Lab Med 2002;126:1326-36.
26. Navarro-Fernández J, de la Morena-Barrio ME, Padilla J, et al. Anti-
thrombin Dublin (p.Val30Glu): a relatively common variant with
moderate thrombosis risk of causing transient antithrombin deficien-
cy. Thromb Haemost. 2016;116. [Epub ahead of print].
27. Daly M, Bruce D, Perry DJ, et al. Antithrombin Dublin (-3 Val-
Glu): an N-terminal variant which has an aberrant signal peptidase
cleavage site. FEBS Lett 1990;273:87-90.
28. Beauchamp NJ, Pike RN, Daly M, et al. Antithrombins Wibble
and Wobble (T85M/K): archetypal conformational diseases with
in vivo latent-transition, thrombosis, and heparin activation. Blood
1998;92:2696-706.
29. Corral J, Vicente V, Carrell RW. Thrombosis as a conformational
disease. Haematologica 2005;90:238-46.
30. Corral J, Vicente V. Puzzling questions on antithrombin: Diagnostic
limitations and real incidence in venous and arterial thrombosis.
Thromb Res 2015;135:1047-8.
31. Di Minno MN, Dentali F, Lupoli R, et al. Mild antithrombin defi-
ciency and risk of recurrent venous thromboembolism: a prospective
cohort study. Circulation 2014;129:497-503.